Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
SCRI HealthONE, Denver, Colorado BRCR Global, Plantation, Florida Memorial Sloan Kettering Cancer Center, New York, New York Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio Vanderbilt University Medical Center, Nashville, Tennessee